Tag: NIH license
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Smarter energy decisions: GridBeyond unveils AI-powered Bid Optimiser in Australia
As Australia’s energy transition accelerates, businesses participating in the National Electricity Market (NEM) are facing growing challenges in managing their energy assets efficiently.
